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Expression of different conformations of p53 in the blast cells of acute
myeloblastic leukaemia is related to in vitro growth characteristics
Y.-M. Zhu, D. Bradbury & N. Russell
Department ofHaematology, Nottingham City Hospital and University ofNottingham, Nottingham, UK.
Summary Expression of the wild-type p53 gene has an important role in cell differentiation, maturation
and apoptosis. Mutation of the p53 gene is associated with tumour development and mutant p53 can promote
cell proliferation. Recently wild-type p53 has been demonstrated to exist in two conformational variants: one
acting as a suppressor (PAb240-/PAbl620+) and one as a promoter (PAb240+/PAbl620-) of cell
proliferation. We have analysed the expression of p53 by flow cytometry in blast cells from 34 patients with
acute myeloblastic leukaemia in relationship to the proliferation characteristics of these cells in a clonogenic
assay. Blasts from three out of 34 patients did not express p53 using the antibodies: PAb421, PAbl8O1,
PAb240 and PAbl620. The remaining 31 samples expressed p53 detected by PAb240 which recognises mutant
p53 and is predicted to recognise wild-type p53 in the promoter conformation. Blasts from 19 out of 31 cells
which expressed PAb240 co-expressed PAbl620, expression of PAbl620 was associated with non-autonomous
growth in vitro. In contrast, the majority of blasts with the p53 phenotype of PAb240 +/PAbl620 - or which
lacked p53 expression exhibited autonomous growth characteristics in vitro. Furthermore expression of
PAbl620 in blasts with autonomous growth cells could be detected following growth inhibition using
monoclonal antibodies against autocrine growth factors. Our data demonstrate that in AML cells, p53
conformation is related to the growth characteristics of the cells and is regulated by either exogenous or
autocrine haematopoietic growth factors.
Wild-type p53 gene has properties consistent with it being the
product of a tumour suppressor gene. Mutations within
highly conserved domains of the p53 gene frequently occur in
wide variety of tumour cells including leukaemic cells
(Sugimoto et al., 1991; Fenaux et al., 1992; Hu et al., 1992).
The products of mutated p53 gene not only lack normal
function but also can convert wild-type p53 to a promoter of
cell proliferation and tumour progression (Marshall, 1991).
Recently evidence has accumulated that wild-type p53 can
exist in two different conformations; one with a suppressor
effect and one with a promoter effect on cell proliferation
(reviewed in Milner, 1991; and Ullrich et al., 1992). These
studies have been facilitated by the differential reactivity of
the two different conformations with a number of p53 mono-
clonal antibodies; PAb421, PAbl801, PAb240 and PAbI620.
Thus Milner (1991) has proposed that the suppressor form of
p53 is PAb1620 +/PAb240- and that the promoter form is
PAb1620 - /PAb240 +, the latter is also the immunopheno-
type of mutant p53.
The blast cells of acute myeloblastic leukaemia (AML) are
a convenient model to study the effect of p53 on cell pro-
liferation. Studies of the in vitro growth characteristics of
AML blasts have revealed considerable heterogeneity. We
have previously classified the growth ofAML blasts into four
groups depending upon their pattern of growth in a blast cell
colony assay. Group 1 cells fail to grow in this system, even
when stimulated by exogenous colony-stimulating factors
(CSF); group 2 cells form colonies but growth is totally
dependent upon exogenous CSFs; group 3 cells exhibit par-
tial autonomous growth which is dependent upon the pro-
duction of autocrine growth factor but growth can be further
stimulated by CSF; finally group 4 cells grow totally
autonomously. The autonomous growth of group 3 and
group 4 cells was found to be related to the production of
autocrine growth factors particularly granulocyte-
macrophage CSF (GM-CSF) and interleukin-l, (Reilly et al.,
1989; Bradbury et al., 1990). Here we have studied the
expression of p53 in AML blasts with different growth char-
acteristics and the effect of stimulation and inhibition of
proliferation on the conformation of p53.
Materials and methods
AML cells
Blood samples were obtained at diagnosis from 34 patients
with AML and peripheral blood blast count of >2 x 1091-.
The diagnosis of AML was made using FAB criteria follow-
ing conventional cytochemical stains and surfaces marker
analysis. Mononuclear cells were separated by Ficoll-
Hypaque sedimentation and samples were depleted of T cells
by Dynabeads M-450 Pan-T (CD-2) (Dynal, Oslo, Norway).
TF-1 which is a human factor-dependent erythroleukaemic
cell line (Kitamura et al., 1989) was kindly donated by Dr
Kitamura (DNAX Research Institute of Molecular and
Biology, Inc. Palo Alto, California, USA).
Colony assay ofAML blasts
Cells were cultured at 2 x I05 cells ml-' in 100 .lI of Iscove's
modified Dulbecco's medium (Flow Labs, Irvine, UK) con-
taining 10% FCS and 0.8% methylcellulose in 100ILI
volumes in 96-well microtitre plates as previously described
(Reilly et al., 1989). Cultures were plated in triplicate in the
presence or absence of a source ofcolony-stimulating activity
provided by medium conditioned by the 5637-human bladder
carcinoma cell line which contains GM-CSF, G-CSF and
IL-1. Colonies of >20 cells were counted after 5-7 days in
culture. For each patient an autostimulatory index (ASI) was
calculated which represents the number of colonies/2 x 104
cells grown in the absence of 5637-CM divided by the
number of colonies/2 x 104 in the presence of 5637-CM.
Patient cells were classified into groups: group 1 blasts failed
to grow in this culture system either autonomously or in
response to 5637-CM; group 2 blasts formed colonies, but
only in the presence of 5637-CM (ASI <0.1); group 3 blasts
produced significant numbers of colonies (> 10/2 x 104 cells
without added 5637-CM, but colony growth size and number
was further stimulated by 5637-CM (ASI 0.1-0.8); group 4
blasts exhibited totally autonomous growth (ASI>0.8).
Antibodies andgrowthfactors
Four purified mouse monoclonal antibodies against p53 were
obtained from Oncogene Science, Inc. (Uniondale, N.Y.,
USA). PAb241 (Ab-1) recognises an epitope of p53 located
between amino acids 370 and 378 (Harlow, 1981); PAbl8O1
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(Ab-2) recognises an epitope between amino acids 32 and 79
(Banks, 1981); PAb240 recognises an epitope between amino
acids 156 and 335 (Gannon, 1990); PAbl620 was developed
by Ball et al. (1984) and has been shown to recognise a
conformational epitope specific for wild-type p53 (Ball et al.,
1984; Milner & Medcalf, 1991). Human recombinant GM-
CSF was a gift from Behring (Frankfurt, Germany). The
sheep anti-human GM-CSF was a gift of Dr A. Gearing,
National Institute for Biological Standards and Control
(NIBSC), London.
Flow cytometry
The blast cells were fixed with 70% cold ethanol for 15 min.
After washing twice with PBS, the fixed cells were incubated
for 30 min at room temperature with the p53 antibody or a
nonspecific mouse IgG monoclonal antibody as a negative
control. The stained cells were washed twice in PBS and then
incubated with a FITC-conjugated rabbit anti-mouse
immunoglobulin (DAKO, Denmark) for a further 30 min. A
total of 10,000 cells were analysed using a FACScan flow
cytometer (Becton Dickinson, USA).
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Statistical methods
Statistically significant differences between the samples of
different groups were determined by Yates' correction.
Results
Blast cells from 34 patients with AML were studied. In three
samples p53 was not detected by any of the antibodies
(AML-32, -33, and -34). All blasts which were p53 negative
expressed totally autonomous growth (Table I). In the
remaining 31 samples, p53 was detected by one or more of
the p53 antibodies as determined by > 10% positive expres-
sion (Table I). Blast cells from all 31 patients were positive
for p53 using PAb240 and blasts from 30 out of 31 (97%)
were positive using PAbl801. The expression of PAb240 and
PAbl801 showed no relationship to growth group. In con-
trast the expression of p53 recognised by PAbl620 more
frequently occurred in AML blasts with characteristics of
non- autonomous growth (group 1 and group 2) than in
those with characteristics of autonomous growth (P <0.01).
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Figure 1 Flow cytometry analysis of p53 protein expression in blast cells from a AML patient (AML-10) at presentation a, and
after relapse b. The fluorescence histograms with anti-p53 antibodies: PAb42l, PAbl8O0, PAb240 and PAbl620 respectively (-)
and the over-histogram with non-specific mouse IgG monoclonal antibody as a negative control (-).
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Table I Expression ofp53 recognised by different anti-p53 monoclonal antibodies in AML blasts related to in
vitro growth characteristics
Patients PAb421 (%) PAbJ801 (%) PAb240 (%) PAb1620 (%)
Group 1 AML-1 26 29 46 27
AML-2 44 91 90 47
AML-3 30 98 89 22
AML-4 61 97 98 56
AML-5 36 99 99 11
AML-6 66 81 97 72
AML-7 65 52 85 64
Group 2 AML-8 25 76 95 33
AML-9 21 89 94 12
AML-10 49 78 79 46
AML-1 14 94 94 22
AML-12 7 73 87 23
AML-13 19 56 73 20
AML-14 9 49 80 4
Group 3 AML-15 5 6 58 6
AML-16 16 13 64 14
AML-17 7 75 28 8
AML-18 2 96 99 3
AML-19 38 60 88 46
AML-20 3 44 99 4
AML-21 22 28 63 18
AML-22 1 51 87 2
Group 4 AML-23 2 98 95 2
AML-24 3 32 84 2
AML-25 6 15 45 6
AML-26 9 84 71 14
AML-27 28 94 94 23
AML-28 19 15 81 6
AML-29 63 55 56 56
AML-30 8 52 68 4
AML-31 4 97 98 5
AML-32 1 1 2 2
AML-33 2 3 5 5
AML-34 1 5 3 3
Group 1 blasts fail to grow in the clonogenic assay used; group 2 blasts are totally dependent upon
exogenous growth factors for colony growth; group 3 blasts exhibit partially autonomous growth
characteristics; group 4 blasts exhibit totally autonomous growth in vitro. % refers to the frequency of positive
cells measured by flow cytometry.
Overall 19 out of 31 (61%) samples were positive with
PAbl620. This included 13 out of 14 samples (93%) with
characteristics of non-autonomous growth (groups 1 and 2),
however, only six out of 17 samples (35%) with characteris-
tics of autonomous growth (groups 3 and 4) were detected by
PAbl620. Using PAb421 18 out of 31 samples were positive,
again the majority of blasts with non-autonomous growth
were positive (12 out of 14 samples) in contrast ony six out
of 17 group 3/group 4 blasts were positive (P <0.01). Thus
groups 1 and 2 blasts with non-autonomous growth charac-
teristics co-expressed p53 in both suppressor (PAbl620 +)
and promoter (PAb240+) conformations whereas blasts with
autonomous growth (groups 3 and 4) were more frequently
only PAb240 +.
The different patterns of p53 expression between AML
blasts with autonomous and non-autonomous growth were
further examined by studying one patient (AML-10), at pre-
sentation and following relapse. Initially the blasts had group
2 growth characteristics and (Figure 1) expressed p53 in both
PAb240 (79%) and PAbl620 (46%) conformations. However
at relapse the growth characteristics had changed to those of
group 3 and the PAbl620 + conformation was no longer
detectable. These data suggested that the expression of p53 in
AML cells closely related to cell proliferation. To investigate
this further we studied the effect of growth stimulation on
group 2 blasts.
As shown in Table II, changes in p53 conformation in
group 2 blasts induced by growth factors provided by 5637-
CM were detected following 48 h ofculture. PAbl620 expres-
sion was reduced and PAb240 expression increased (Table
II). Similar results were obtained in the TF- 1 factor-
dependent erythroleukaemia cell line. When cell growth was
induced by rGM-CSF, PAbl620 expression was present in
<5% of cells, however 48 h following withdrawal of GM-
CSF, PAb1620 expression was increased to 26%. Conforma-
tional change of p53 was also found in groups 3 and 4 blasts
treated with an anti-GM-CSF antibody which inhibits pro-
liferation of these cells (Reilly et al., 1989). In three blasts
Table II Changes in the conformation of p53 following culture of group 2
(CSF-dependent) blasts and TF-1 cells with haemopoietic growth factors
NCM (%) 5637-CM/rhGM-CSF (%)
PatientsITF-I PAb240 PAb1620 PAb240 PAb1620
AML-8a 95 33 98 4
AML-11a 94 22 98 2
AML-12a 87 23 93 1
AML-13a 73 20 84 2
TF-1b 95 26 95 5
NCM: no condition medium. 5637-CM: 5637-conditioned medium. aCell
growth was induced by 5637-CM. bCell growth was induced by rhGM-CSF.854 Y.-M. ZHU et al.
Table III Effect of suppression of autocrine growth factors on conformation
of p53 in blasts with autonomous growth characteristics
NCM (%) Anti-GM-CSF (%)
Patients PAb240 PAb1620 PAb240 PAb1620
AML-18 99 3 89 20
AML-22 87 2 67 13
AML-23 95 2 55 12
NCM: no condition medium. Anti-GM-CSF: culture medium including
anti-GM-CSF antibody.
tested, PAb1620 expression was increased following incuba-
tion with anti-GM-CSF and PAb240 expression was reduced
(Table III).
Discussion
We have investigated the expression and conformation of p53
in blast cells from 34 patients with AML by flow cytometry
using four different monoclonal antibodies. In blasts from
three patients, p53 was not detectable by any of these
antibodies, a finding which had previously been reported by
others (Zhang et al., 1992). Blasts from these three patients
all exhibited totally autonomous (group 4) growth in vitro.
We have previously shown that the autonomous growth of
AML blasts is related to the production of autocrine growth
factors including GM-CSF and IL-P (Reilly et al., 1989;
Bradbury et al., 1990). Our data here suggest that the
acquisition of autonomous growth characteristics by AML
blasts may also involve the inactivation of growth inhibitory
proteins such as wild-type p53. We have also recently shown
that deletion of retinoblastoma (Rb) protein is common in
AML blasts with autonomous growth. It is of interest that
blasts from the three patients which were p53 negative were
also negative for Rb protein expression (data not shown) a
protein which also normally suppresses cell proliferation.
Blast cells from the remaining 31 patients all expressed p53
detected by PAb240. Similar results have recently been
reported in chronic myeloid leukaemia cells (Lanza et al.,
1991), also Zhang et al. (1992) detected p53 recognised by
PAb240 in 32 out of 37 (86%) of AML samples using
immunoprecipitation. However p53 mutations as detected by
PCR-SSCP (polymerase chain reaction-single strand confor-
mation polymorphism) and sequence analysis were only
detected in three of these samples. Several research groups
have already reported that p53 in normal haematopoetic cells
is also recognised by PAb240 (Rivas et al., 1992; Lanza et al.,
1992; Zhang et al., 1992) and indeed we have also detected
PAb240 positive normal bone marrow cells (data not shown).
Therefore expression of p53 recognised by PAb240 is not
evidence for mutant p53 in haematopoietic cells including
AML blasts, but rather indicates the presence of wild-type
p53 in the promoter conformation.
Unlike other previous reports which have used
immunoprecipitation (Zhang et al., 1992), we detected p53
using the antibody PAbl620 in blasts from 19 out of 31
patients. PAbl620 recognises p53 in the suppressor confor-
mation (Milner & Medcalf, 1991). Thus our data would
suggest that p53 with the suppressor (PAb1620 +/PAb240 -)
and the promoter (PAb1620 -/PAb240 +) conformation are
present within the same cell population. Of interest was the
finding that the PAb1620 + conformation was associated
with the presence of non-autonomous growth in vitro. How-
ever following growth stimulation of group 2 blasts with
5637-CM the expression of PAb1620 fell and that PAb240
increased. We further investigated the effect of growth
stimulation on p53 expression in the TF-I erythroleukaemia
cell line. TF-1 is a factor-dependent cell line requiring GM-
CSF for proliferation (Kitamura et al., 1989). In active pro-
liferation the cells are PAb240 +.PAbl620 -. However
within 48 h of removal of GM-CSF from the cultures, TF-1
cells expressed p53 in the PAbl620 conformation. These data
would indicate that the presence of p53 in the PAbl620 +
conformation is associated with growth arrest of leukaemic
cells even in the presence of p53 in the promoter (PAb240 +)
form. Cells which have been stimulated with exogenous
growth factors or which produce autocrine growth factors
are thus characteristically PAb240 +, PAbl620 -. As a cor-
ollary to this treatment of AML blasts with autonomous
growth characteristics using anti-GM-CSF which is
associated with growth inhibition, was associated with in-
creased PAbl620 expression and reduction in PAb240. In all
of these studies expression of PAbl620 was associated with
PAb421 expression suggesting that unlike previous studies,
PAb421 recognises p53 in the suppressor conformation
similar to PAbl620.
The relationship between growth characteristics and p53
expression in AML blasts was further illuminated by studies
on one patient's cells at presentation and after relapse.
Initially the cells expressed p53 in both promoter and sup-
pressor conformations and exhibited group 2 growth.
Analysis at relapse revealed a change in the growth charac-
teristics of the cells with the presence of partially
autonomous growth and which were now PAbl620 negative.
It has been suggested that normal function of p53 may be
related to cell differentiation and programmed cell death
(apoptosis) (Yonish-Rouach et al., 1991). Thus wild-type p53
induced apoptosis when introduced into murine leukaemic
cells which normally lack p53. It is possible that the presence
of p53 in the mutant or promoter (PAb240 +/PAbl620-)
conformation, or its complete absence in blast cells with
autonomous growth may be important in preventing
apoptotic cell death in these AML cells.
We have recently shown that patients whose AML cells
exhibit autonomous growth characteristics (groups 3 and 4
blasts) have a low remission induction rate and a significantly
reduced survival compared to the non-autonomous growth
group (Hunter et al., 1993). The effect of autocrine growth
factors in maintaining p53 in the promoter PAb240 + con-
formation may prevent apoptotic cell death and thus may be
one mechanism accounting for the poor survival of this
group of patients.
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